ArticleMedicine2025
Juvenile xanthogranuloma as a potential early manifestation of neurofibromatosis type 1: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleJuvenile xanthogranuloma (JXG), the most common form of non-Langerhans cell histiocytosis, typically presents in early childhood and often resolves spontaneously. Due to its generally favorable prognosis, physical examination may be overlooked. However, JXG has increasingly been associated with neurofibromatosis type 1 (NF1), highlighting the need for comprehensive evaluation. PATIENT CONCERN: The patients were 14-month-old twin toddlers who presented to the outpatient clinic with multiple yellow papules on the scalp, first noted 2 months prior. DIAGNOSIS: Physical examination revealed multiple yellow papules on the scalp, with dermoscopy showing the characteristic "setting sun" sign. Additionally, 10 to 20 café-au-lait macules of varying sizes were observed on the limbs and trunk. Genetic testing confirmed a mutation in the NF1 gene. Based on these findings, a final diagnosis of JXG associated with NF1 was made.
interventionsComprehensive tests, including complete blood count, liver and kidney function tests, lipid profile, ophthalmologic screening, and brain magnetic resonance imaging, were performed on both patients. All results were unremarkable. Given the self-limiting nature of scalp JXG, no specific treatment was initiated, and regular follow-up was arranged. OUTCOMES: At 1-year follow-up, one twin developed a biopsy-confirmed plexiform neurofibroma and is scheduled to begin selumetinib therapy. The other twin remains asymptomatic under close monitoring. LESSONS: Patients with JXG, especially those under the age of 2, should undergo a thorough physical examination to evaluate for NF1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.